Role of biological agents inflammatory diseases

被引：29

作者：

Efthimiou, P ^{[1
]}

Markenson, JA ^{[1
]}

机构：

[1] Cornell Univ, Weill Med Coll, Hosp Special Surg, New York, NY 10021 USA

来源：

SOUTHERN MEDICAL JOURNAL | 2005年 / 98卷 / 02期

关键词：

biological therapy; IL-1 receptor antagonist; psoriatic arthritis; rheumatoid arthritis; TNF-alpha inhibitors;

D O I：

10.1097/01.SMJ.0000153119.37032.8B

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A new era in the treatment of immune-mediated inflammatory disorders has begun with the clinical availability of anticytokine therapy. Biological agents that are currently available include 3 agents that decrease the activity of tumor necrosis factor-alpha (infliximab, adalimumab, etanercept) and an interleukin-1 receptor antagonist (anakinra), with many more in development. Those extraordinarily effective medications are an important addition to our therapeutic armamentarium, and, although originally developed for rheumatoid arthritis and Crohn disease, have been found to be efficacious in the treatment of seronegative spondyloarthropathies (psoriatic arthritis, ankylosing spondylitis) and juvenile rheumatoid arthritis. Their role is currently being defined in other autoimmune disorders such as uveitis, sarcoidosis, interstitial lung disease, vasculitis, inflammatory myopathies, graft-versus-host disease, and Sjogren syndrome.

引用

页码：192 / 204

页数：13

共 105 条

[31] Anti-interleukin-1 therapy in rheumatic diseases [J].

Dayer, JM ;

Feige, U ;

Edwards, CK ;

Burger, D .

CURRENT OPINION IN RHEUMATOLOGY, 2001, 13 (03) :170-176

[32]

den Broeder A, 2002, J RHEUMATOL, V29, P2288

[33]

EFTHIMIOU P, 2003, HOSP HEALTHCARE EURO, pP38

[34]

EFTHIMIOU P, 2003, ACR 2003 ORL FL

[35] Infections and anti-tumor necrosis factor α therapy [J].

Ellerin, T ;

Rubin, RH ;

Weinblatt, ME .

ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3013-3022

[36] RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS [J].

ELLIOTT, MJ ;

MAINI, RN ;

FELDMANN, M ;

KALDEN, JR ;

ANTONI, C ;

SMOLEN, JS ;

LEEB, B ;

BREEDVELD, FC ;

MACFARLANE, JD ;

BIJL, H ;

WOODY, JN .

LANCET, 1994, 344 (8930) :1105-1110

[37]

ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362

[38]

Emery P, 2003, ARTHRITIS RHEUM, V48, pS313

[39]

Feldmann M, 2001, CURR DIRECT AUTOIMMU, V3, P188

[40] Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis - A large, international, multicenter, placebo-controlled trial [J].

Fleischmann, RM ;

Schechtman, J ;

Bennett, R ;

Handel, ML ;

Burmester, GR ;

Tesser, J ;

Modafferi, D ;

Poulakos, J ;

Sun, G .

ARTHRITIS AND RHEUMATISM, 2003, 48 (04) :927-934

← 1 2 3 4 5 6 7 8 9 10 →